|
|
 Previous Article | Table of Contents | Next Article 
Molecular quantification of residual disease in chronic myelogenous
leukemia after bone marrow transplantation
JD Thompson, I Brodsky and JJ Yunis
Department of Neoplastic Diseases, Hahnemann University, Philadelphia, PA.
Residual disease remains a major problem in the treatment of human
neoplasia. To effectively monitor minimal leukemic activity after bone
marrow transplantation (BMT), we used a competitive polymerase chain
reaction (PCR) amplification technique to quantify expression of the
characteristic bcr-abl fusion message in patients with chronic myelogenous
leukemia (CML). Quantitative results were obtained between the 0.001% and
0.1% level in control experiments. This represents a significant advantage
over cytogenetic and Southern blotting techniques routinely used to
diagnose CML, which may not be sensitive below the 1% level. To illustrate
the potential clinical usefulness of the quantitative PCR strategy, we
compared results of bcr-abl messenger RNA expression with those obtained
using cytogenetic and Southern blotting techniques, in a study of
consecutive BM and peripheral blood (PB) samples from two CML patients at
high risk for relapse after BMT. One patient received a syngeneic
transplant during the chronic phase of the disease and relapse was apparent
at the molecular level 4.5 months after BMT, while the patient was in
complete clinical remission. The second patient was treated with an
allogeneic BMT during the accelerated phase of the disease. A slow, but
progressive decrease in bcr-abl expression was observed during the first 12
months after BMT, and expression was undetectable thereafter. Our results
indicate that the competitive PCR technique can be used to monitor disease
activity in patients at high risk of relapse, while the patients are in
complete clinical remission, which should facilitate the early detection of
relapse or the identification of progressive disappearance of leukemic
activity. The approach used may serve as a model for the study of residual
disease in an increasing number of other hematologic malignancies that
express cancer-specific RNAs.
Volume 79,
Issue 6,
pp. 1629-1635,
03/15/1992
Copyright © 1992 by The American Society of Hematology
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
B. Fang, C. Zheng, L. Liao, Q. Han, Z. Sun, X. Jiang, and R. C. H. Zhao
Identification of human chronic myelogenous leukemia progenitor cells with hemangioblastic characteristics
Blood,
April 1, 2005;
105(7):
2733 - 2740.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Branford, Z. Rudzki, I. Parkinson, A. Grigg, K. Taylor, J. F. Seymour, S. Durrant, P. Browett, A. P. Schwarer, C. Arthur, et al.
Real-time quantitative PCR analysis can be used as a primary screen to identify patients with CML treated with imatinib who have BCR-ABL kinase domain mutations
Blood,
November 1, 2004;
104(9):
2926 - 2932.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. Yu, M. S. Kruskall, J. J. Yunis, J. H.M. Knoll, L. Uhl, S. Alosco, M. Ohashi, O. Clavijo, Z. Husain, E. J. Yunis, et al.
Disputed Maternity Leading to Identification of Tetragametic Chimerism
N. Engl. J. Med.,
May 16, 2002;
346(20):
1545 - 1552.
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Meijerink, C. Mandigers, L. van de Locht, E. Tönnissen, F. Goodsaid, and J. Raemaekers
A Novel Method to Compensate for Different Amplification Efficiencies between Patient DNA Samples in Quantitative Real-Time PCR
J. Mol. Diagn.,
May 1, 2001;
3(2):
55 - 61.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
E. Olavarria, E. Kanfer, R. Szydlo, J. Kaeda, K. Rezvani, K. Cwynarski, C. Pocock, F. Dazzi, C. Craddock, J. F. Apperley, et al.
Early detection of BCR-ABL transcripts by quantitative reverse transcriptase-polymerase chain reaction predicts outcome after allogeneic stem cell transplantation for chronic myeloid leukemia
Blood,
March 15, 2001;
97(6):
1560 - 1565.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. Barbany, A. Hagberg, U. Olsson-Stromberg, B. Simonsson, A.-C. Syvanen, and U. Landegren
Manifold-assisted Reverse Transcription-PCR with Real-Time Detection for Measurement of the BCR-ABL Fusion Transcript in Chronic Myeloid Leukemia Patients
Clin. Chem.,
July 1, 2000;
46(7):
913 - 920.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. Cimino, L. Elia, M. C. Rapanotti, T. Sprovieri, M. Mancini, A. Cuneo, C. Mecucci, G. Fioritoni, M. Carotenuto, E. Morra, et al.
A prospective study of residual-disease monitoring of the ALL1/AF4 transcript in patients with t(4;11) acute lymphoblastic leukemia
Blood,
January 1, 2000;
95(1):
96 - 101.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. Lion;, S. Faderl, M. Talpaz, H. M. Kantarjian, and Z. Estrov
Monitoring of Residual Disease in Chronic Myelogenous Leukemia by Quantitative Polymerase Chain Reaction and Clinical Decision Making
Blood,
August 15, 1999;
94(4):
1486 - 1488.
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Hoyle, C. D. Bangs, P. Chang, O. Kamel, B. Mehta, and R. S. Negrin
Expansion of Philadelphia Chromosome-Negative CD3+CD56+ Cytotoxic Cells From Chronic Myeloid Leukemia Patients: In Vitro and In Vivo Efficacy in Severe Combined Immunodeficiency Disease Mice
Blood,
November 1, 1998;
92(9):
3318 - 3327.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. P. Hunger, M. Z. Fall, B. M. Camitta, A. J. Carroll, M. P. Link, S. J. Lauer, D. H. Mahoney, D. Jeanette Pullen, J. J. Shuster, C. Philip Steuber, et al.
E2A-PBX1 Chimeric Transcript Status at End of Consolidation Is Not Predictive of Treatment Outcome in Childhood Acute Lymphoblastic Leukemias With a t(1;19)(q23;p13): A Pediatric Oncology Group Study
Blood,
February 1, 1998;
91(3):
1021 - 1028.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
